Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00171873
Recruitment Status : Unknown
Verified May 2012 by Carmen Schade-Brittinger, Philipps University Marburg Medical Center. Recruitment status was: Active, not recruiting
First Posted : September 15, 2005
Results First Posted : March 28, 2011
Last Update Posted : May 10, 2012
Information provided by (Responsible Party):
Carmen Schade-Brittinger, Philipps University Marburg Medical Center
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
the PI's rights to discuss or publish trial results after the trial is completed.
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
Results Point of Contact
Layout table for Results Point of Contact information